Technology
Health
Biotechnology

Axovant Gene Therapies

$6.92
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.30 (4.53%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell AXGT and other stocks, options, ETFs, and crypto commission-free!

About AXGT

Axovant Gene Therapies Ltd. Common Shares, also called Axovant Gene Therapies, is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Read More Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. The company was founded on October 31, 2014 and is headquartered in London, United Kingdom.

Employees
57
Headquarters
London, London & South East
Founded
2014
Market Cap
157.64M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
197.20K
High Today
$6.94
Low Today
$6.48
Open Price
$6.68
Volume
107.61K
52 Week High
$20.80
52 Week Low
$3.81

Collections

Technology
Health
Biotechnology
Gene Therapies
Medical
Biopharmaceutical
Pharmaceutical
2015 IPO

AXGT News

BenzingaAug 12

Voyager Therapeutics - Axovant Analyst Turns Bullish Ahead Of Q4 Gene Therapy Data Readouts

178

AXGT Earnings

-$1.23
-$0.88
-$0.53
-$0.18
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
-$0.91 per share
Actual
-$1.23 per share

More AXGT News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.